Seeking Alpha

Robert Schwartz

 
View as an RSS Feed
View Robert Schwartz's Comments BY TICKER:
Latest  |  Highest rated
  • NewLink Genetics: Examining Likelihood Of Success In The Impress Trial [View article]
    That is correct.
    Jan 28, 2015. 08:40 AM | Likes Like |Link to Comment
  • NewLink Genetics: Examining Likelihood Of Success In The Impress Trial [View article]
    Not all, I continue to believe that trial will fail.
    Jan 27, 2015. 08:35 AM | Likes Like |Link to Comment
  • NewLink Genetics: Examining Likelihood Of Success In The Impress Trial [View article]
    A well-written and researched assessment.
    Jan 8, 2015. 05:37 PM | Likes Like |Link to Comment
  • Newlink Genetics' Pancreatic Cancer Vaccine Likely To Disappoint Investors In 2013 [View article]
    I hope so.
    Jan 7, 2015. 10:09 AM | Likes Like |Link to Comment
  • Peregrine Pharmaceuticals' Bavituximab: It's Time To Throw In The Towel [View article]
    The Sunrise trial is comparing Bavituximab + docetaxel vs. docetaxel and, as I mentioned previously, there are NO RANDOMIZED data available to portend success. That is why the "drug" hasn't been scooped up by big pharma and why the stock is trading at levels of LOW anticipation.

    The only hope for Bavituximab is one of BMY's immune stimulants and I would characterize that as a "long shot".
    Jan 6, 2015. 02:30 PM | Likes Like |Link to Comment
  • Newlink Genetics' Pancreatic Cancer Vaccine Likely To Disappoint Investors In 2013 [View article]
    The trial will fail.
    Jan 6, 2015. 02:18 PM | 1 Like Like |Link to Comment
  • Why AVEO Pharmaceuticals' Tivozanib Will Be Approved For The Treatment Of Advanced Renal Cell Carcinoma [View article]
    Thanks Pete, will try and find the time.
    Dec 7, 2013. 10:20 AM | Likes Like |Link to Comment
  • Why AVEO Pharmaceuticals' Tivozanib Will Be Approved For The Treatment Of Advanced Renal Cell Carcinoma [View article]
    It's early but I readily acknowledge my miss on AVEO!
    Dec 6, 2013. 09:07 AM | 1 Like Like |Link to Comment
  • Why AVEO Pharmaceuticals' Tivozanib Will Be Approved For The Treatment Of Advanced Renal Cell Carcinoma [View article]
    I am still a GALE bear and haven't yet done diligence assessments on IMUC or NW.
    Dec 5, 2013. 09:25 AM | Likes Like |Link to Comment
  • Why AVEO Pharmaceuticals' Tivozanib Will Be Approved For The Treatment Of Advanced Renal Cell Carcinoma [View article]
    They have certainly had a good run of late!
    Dec 3, 2013. 08:19 AM | Likes Like |Link to Comment
  • Peregrine Pharmaceuticals' Bavituximab: It's Time To Throw In The Towel [View article]
    My advice was that investors throw in the towel. PPHM will not throw in the towel until the goose stops producing their salaries.

    Their data doesn't merit a BTD.
    Nov 25, 2013. 05:09 PM | Likes Like |Link to Comment
  • Quick Take On Vical's Allovectin Failure [View article]
    Excellent summary!
    Aug 14, 2013. 01:30 PM | 1 Like Like |Link to Comment
  • Newlink Genetics' Pancreatic Cancer Vaccine Likely To Disappoint Investors In 2013 [View article]
    Patrick is usually correct when making PTRS predictions so perhaps I was overly optimistic,
    Jul 18, 2013. 03:21 PM | 2 Likes Like |Link to Comment
  • Newlink Genetics' Pancreatic Cancer Vaccine Likely To Disappoint Investors In 2013 [View article]
    Thanks for the question. The 15-20% number refers to the probability of a successful Phase-III outcome and I still stand by this number.

    Regards,

    Robert
    Jul 17, 2013. 01:42 PM | Likes Like |Link to Comment
  • Peregrine Pharmaceuticals' Bavituximab: It's Time To Throw In The Towel [View article]
    The FDA will expedite approval of drugs with the so-called "Breakthrough Designation". The designation does not obviate the need to conduct studies that demonstrate the effectiveness of the drug.

    I said that a large, well-powered study would have been required for PPHM to have garnered an SPA for Bavi. The elected not to do the study recommended by FDA and the approval of Bavi (assuming a positive Phase III trial) will be a review issue.

    I good sized study is necessary to "tease out" the differential activity of the Bavi combination.

    Robert
    May 31, 2013. 01:38 PM | Likes Like |Link to Comment
COMMENTS STATS
188 Comments
49 Likes